An approach to the validation of markers for use in AIDS clinical trials
- PMID: 9142767
- DOI: 10.1093/clinids/24.5.764
An approach to the validation of markers for use in AIDS clinical trials
Abstract
Dr. Mildvan and coauthors have thoroughly reviewed and documented what is known about the validation of surrogate markers for use in clinical trials. They have proposed a classification system based on the usefulness of available immunologic and virological assays as measures of prognosis, drug activity, and therapeutic efficacy. The latter, a type II marker in the proposed classification, should estimate the proportion of treatment effect explained by change in the marker induced by therapy and, if complete, can substitute for clinical endpoints. HIV clinical trialists have had a long-standing interest in using surrogates for clinical endpoints to facilitate conduct of experimental protocols and to decrease the time and effort required to develop new treatment strategies. The approach outlined in this review by experienced clinicians, biostatisticians, and immunologists provides a framework to evaluate currently available and potential surrogate markers.
Similar articles
-
Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties.Clin Infect Dis. 1993 Feb;16 Suppl 1:S22-5. doi: 10.1093/clinids/16.supplement_1.s22. Clin Infect Dis. 1993. PMID: 8093844
-
Estimating the proportion of treatment effect explained by a surrogate marker.Stat Med. 1997 Jul 15;16(13):1515-27. doi: 10.1002/(sici)1097-0258(19970715)16:13<1515::aid-sim572>3.0.co;2-1. Stat Med. 1997. PMID: 9249922
-
Statistical evaluation of surrogate markers: validity, efficiency, and sensitivity.Clin Trials. 2013 Oct;10(5):693-5. doi: 10.1177/1740774513499652. Epub 2013 Aug 29. Clin Trials. 2013. PMID: 23988465
-
Analyzing laboratory marker changes in AIDS clinical trials.J Acquir Immune Defic Syndr (1988). 1991;4(7):667-76. J Acquir Immune Defic Syndr (1988). 1991. PMID: 2051307 Review.
-
Perspective: human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: issues in interim monitoring and early stopping.J Infect Dis. 1998 Mar;177(3):761-5. doi: 10.1086/514244. J Infect Dis. 1998. PMID: 9498459 Review.
Cited by
-
PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- against.Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1466-72. doi: 10.1007/s00259-005-1937-2. Eur J Nucl Med Mol Imaging. 2005. PMID: 16283180 No abstract available.
-
Toward the validation of functional neuroimaging as a potential biomarker for Alzheimer's disease: implications for drug development.Mol Imaging Biol. 2005 Jan-Feb;7(1):59-68. doi: 10.1007/s11307-005-0953-8. Mol Imaging Biol. 2005. PMID: 15912277 Review.
-
Study design issues in evaluating immune biomarkers.Curr Opin HIV AIDS. 2013 Mar;8(2):147-54. doi: 10.1097/COH.0b013e32835d3259. Curr Opin HIV AIDS. 2013. PMID: 23380656 Free PMC article. Review.
-
Immune Correlates of Herpes Zoster in People Living with HIV on Effective Antiretroviral Therapy.AIDS Res Hum Retroviruses. 2019 Oct;35(10):890-895. doi: 10.1089/AID.2019.0053. Epub 2019 Jul 16. AIDS Res Hum Retroviruses. 2019. PMID: 31179712 Free PMC article.
-
A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials.Curr Drug Targets. 2010 May;11(5):536-45. doi: 10.2174/138945010791011947. Curr Drug Targets. 2010. PMID: 20199395 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
